Project Grant R00HL177179
Award Date 8/1/26
Completion Date 6/30/29
Dollars Obligated $249K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Augusta, GA 30912, USA
Similar Awards
- The National Heart, Lung, and Blood Institute awarded the University of Pittsburgh $1,384,453 on September 15, 2025, under the Cardiovascular Diseases Research program (CFDA 93.837) to investigate the non-canonical roles of NIPBL in cardiomyocytes. The research addresses a gap in understanding why heterozygous NIPBL mutations—which account for over 60 percent of Cornelia de Lange Syndrome (CDLS) cases—lead to congenital heart disease or decreased cardiac function in at least 30 percent of CDLS...
- The National Heart, Lung, and Blood Institute awarded Augusta University Research Institute, Inc. $1,518,002 on September 15, 2025, under the Cardiovascular Diseases Research program (CFDA 93.837) to investigate posttranslational control of vascular smooth muscle cell identity and vascular health through neddylation mechanisms in coronary artery disease. The award funds research into the role of neddylation—specifically NEDD8 activating enzyme 1 (NAE1)-mediated protein modification—in vascular...
- The National Heart, Lung, and Blood Institute awarded the Trustees of Boston University $849,790 on September 1, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to decode regulatory variants in cardiovascular disease through functional annotation of non-coding variants associated with CVD. The recipient will characterize non-coding regulatory variants and their mechanisms using high-throughput experimental approaches in human cardiomyocytes. Aim 1 encompasses biophysical...
- The National Heart, Lung, and Blood Institute awarded the University of Virginia $776,745 on August 17, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to define and target DELE1-mediated mitochondrial stress signaling in cardiomyopathy. The research addresses how mitochondrial dysfunction drives cardiovascular disease, including heart failure and ischemic injury, by characterizing the molecular mechanisms through which DELE1 acts as a mitochondrial stress sensor to...
- The National Heart, Lung, and Blood Institute awarded The University of Chicago $817,976 on August 1, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to develop single molecule footprinting methods for studying gene regulation in cardiac differentiation and disease. The recipient will combine methyltransferase-based chromatin measurement with native long-read sequencing to assess chromatin accessibility, nucleosome positioning, transcription factor binding, and DNA...
- The National Heart, Lung, and Blood Institute awarded J. David Gladstone Institutes $131,307 on July 21, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to support a K99/R00 career development project investigating chromatin and spatial mechanisms underlying congenital heart defects in Down syndrome. The research, led by Dr. Feiya Li, dissects how increased dosage of the HMGN1 gene on chromosome 21 alters chromatin structure, gene regulation, and spatial cell signaling...
- The National Heart Lung and Blood Institute awarded the Beckman Research Institute of the City of Hope $813,810 on September 1, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to conduct research on nucleotide supplementation as a treatment strategy for ischemic heart disease and myocardial infarction. The project investigates the role of nucleotide balance in cardiomyocyte proliferation and aims to apply these findings for cardiac repair using large animal models....
- The National Heart, Lung, and Blood Institute awarded the University of Washington $2.815 million on September 24, 2025, under CFDA 93.837 (Cardiovascular Diseases Research) to conduct proteomic and genomic discovery of molecular targets linked to atrial cardiopathy-related cardiovascular outcomes. The award funds research using proteomics and genomic methods across primary and secondary prevention populations to identify novel proteins that may serve as causal risk factors for atrial...
- The National Heart, Lung, and Blood Institute awarded Emory University $498,155 on July 1, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to investigate mechanisms controlling macrophage response during heart regeneration in zebrafish as a model for understanding therapeutic pathways in human cardiac repair. The project, titled "Mechanisms Controlling Macrophage Response During Heart Regeneration in Zebrafish," runs through March 31, 2030, with performance in...
- The National Heart, Lung, and Blood Institute awarded Albert Einstein College of Medicine $693,151 on September 1, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to investigate the germline genetic mechanisms underlying clonal hematopoiesis of indeterminate potential (CHIP). The research will examine how noncoding germline genetic variants confer increased risk of CHIP development by influencing the expansion of mutant hematopoietic stem and progenitor cell clones. Work...